API

Mechanism of Action

The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV (both Type II topoisomerases), which are required for bacterial DNA replication, transcription, repair, and recombination.

Indication

CIPRO is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated:
• Skin and Skin Structure Infections
• Bone and Joint Infections
• Complicated Intra-Abdominal Infections
• Infectious Diarrhea
• Typhoid Fever (Enteric Fever)
• Uncomplicated Cervical and Urethral Gonorrhea
• Inhalational Anthrax post-exposure in adult and pediatric patients
• Plague in adult and pediatric patients
•  Chronic Bacterial Prostatitis
•  Lower Respiratory Tract Infections
o Acute Exacerbation of Chronic Bronchitis
•  Urinary Tract Infections
o Urinary Tract Infections (UTI)
o Acute Uncomplicated Cystitis
o Complicated UTI and Pyelonephritis in Pediatric Patients
•  Acute Sinusitis

Usage
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CIPRO and other antibacterial drugs, CIPRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria